Does the media refer more to ELAN or ARQT?

In the previous week, Elanco Animal Health and Elanco Animal Health both had 4 articles in the media. Elanco Animal Health's average media sentiment score of 1.45 beat Arcutis Biotherapeutics' score of 0.89 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RDY or ARQT?

Arcutis Biotherapeutics has a consensus price target of $34.00, indicating a potential upside of 25.93%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Arcutis Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media prefer RDY or ARQT?

In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for Arcutis Biotherapeutics and 2 mentions for Dr. Reddy's Laboratories. Arcutis Biotherapeutics' average media sentiment score of 0.89 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Arcutis Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARQT or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 1 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 5 mentions for Arrowhead Pharmaceuticals and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.89 beat Arrowhead Pharmaceuticals' score of 0.86 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ARQT or SMMT?

In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Summit Therapeutics. MarketBeat recorded 4 mentions for Arcutis Biotherapeutics and 2 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.94 beat Arcutis Biotherapeutics' score of 0.89 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NUVL or ARQT?

In the previous week, Nuvalent and Nuvalent both had 4 articles in the media. Arcutis Biotherapeutics' average media sentiment score of 0.89 beat Nuvalent's score of 0.72 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Arcutis Biotherapeutics (ARQT) Competitors

$27.00 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$26.22 -0.77 (-2.87%)

As of 06:33 AM Eastern

Compare

ARQT vs. ELAN, RDY, ARWR, SMMT, and NUVL

Should you buy Arcutis Biotherapeutics stock or one of its competitors? MarketBeat compares Arcutis Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcutis Biotherapeutics include Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), Arrowhead Pharmaceuticals (ARWR), Summit Therapeutics (SMMT), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Elanco Animal Health has a beta of 1.69, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Arcutis Biotherapeutics has a net margin of -0.57% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Arcutis Biotherapeutics has lower revenue, but higher earnings than Elanco Animal Health. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.60	-$232M	-$0.50	N/A
Arcutis Biotherapeutics	$376.07M	8.98	-$16.14M	-$0.03	N/A

Elanco Animal Health presently has a consensus price target of $28.55, indicating a potential upside of 16.23%. Arcutis Biotherapeutics has a consensus price target of $34.00, indicating a potential upside of 25.93%. Given Arcutis Biotherapeutics' higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

97.5% of Elanco Animal Health shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Elanco Animal Health and Elanco Animal Health both had 4 articles in the media. Elanco Animal Health's average media sentiment score of 1.45 beat Arcutis Biotherapeutics' score of 0.89 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Elanco Animal Health beats Arcutis Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Dr. Reddy's Laboratories has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.59	$456M	$0.58	26.53
Arcutis Biotherapeutics	$376.07M	8.98	-$16.14M	-$0.03	N/A

In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for Arcutis Biotherapeutics and 2 mentions for Dr. Reddy's Laboratories. Arcutis Biotherapeutics' average media sentiment score of 0.89 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Arcutis Biotherapeutics' net margin of -0.57%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Dr. Reddy's Laboratories has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market.

Arcutis Biotherapeutics has a consensus price target of $34.00, indicating a potential upside of 25.93%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Dr. Reddy's Laboratories and Arcutis Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Arrowhead Pharmaceuticals?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

Arcutis Biotherapeutics has a net margin of -0.57% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Arcutis Biotherapeutics' return on equity of -1.41% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Arcutis Biotherapeutics currently has a consensus target price of $34.00, suggesting a potential upside of 25.93%. Arrowhead Pharmaceuticals has a consensus target price of $86.36, suggesting a potential upside of 9.47%. Given Arcutis Biotherapeutics' higher probable upside, equities analysts plainly believe Arcutis Biotherapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Arrowhead Pharmaceuticals has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.98	-$16.14M	-$0.03	N/A
Arrowhead Pharmaceuticals	$829.45M	13.40	-$1.63M	-$2.15	N/A

In the previous week, Arrowhead Pharmaceuticals had 1 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 5 mentions for Arrowhead Pharmaceuticals and 4 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.89 beat Arrowhead Pharmaceuticals' score of 0.86 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Arrowhead Pharmaceuticals beats Arcutis Biotherapeutics on 9 of the 17 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Summit Therapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Summit Therapeutics has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Summit Therapeutics	N/A	-291.24%	-243.07%

Arcutis Biotherapeutics has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.32, suggesting that its share price is 232% less volatile than the broader market.

In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Summit Therapeutics. MarketBeat recorded 4 mentions for Arcutis Biotherapeutics and 2 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.94 beat Arcutis Biotherapeutics' score of 0.89 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has higher revenue and earnings than Summit Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.98	-$16.14M	-$0.03	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

4.6% of Summit Therapeutics shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Arcutis Biotherapeutics currently has a consensus price target of $34.00, suggesting a potential upside of 25.93%. Summit Therapeutics has a consensus price target of $27.23, suggesting a potential upside of 94.33%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47

Summary

Arcutis Biotherapeutics and Summit Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Nuvalent has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Arcutis Biotherapeutics has higher revenue and earnings than Nuvalent. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Arcutis Biotherapeutics	$376.07M	8.98	-$16.14M	-$0.03	N/A

97.3% of Nuvalent shares are owned by institutional investors. 5.0% of Nuvalent shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Nuvalent and Nuvalent both had 4 articles in the media. Arcutis Biotherapeutics' average media sentiment score of 0.89 beat Nuvalent's score of 0.72 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvalent presently has a consensus price target of $127.73, suggesting a potential upside of 3.41%. Arcutis Biotherapeutics has a consensus price target of $34.00, suggesting a potential upside of 25.93%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nuvalent has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

Summary

Arcutis Biotherapeutics beats Nuvalent on 11 of the 14 factors compared between the two stocks.

Get Arcutis Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARQT vs. The Competition

Export

Metric	Arcutis Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.38B	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-899.70	21.75	25.91	24.17
Price / Sales	8.98	340.46	548.81	101.11
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	17.42	8.31	10.82	6.38
Net Income	-$16.14M	$23.92M	$3.58B	$337.00M
7 Day Performance	1.28%	1.93%	1.90%	-0.23%
1 Month Performance	25.82%	-0.41%	-0.26%	-1.40%
1 Year Performance	96.51%	65.22%	34.40%	27.76%

Arcutis Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARQT Arcutis Biotherapeutics	3.3247 of 5 stars	$27.00 flat	$34.00 +25.9%	+96.5%	$3.38B	$376.07M	N/A	150
ELAN Elanco Animal Health	3.6862 of 5 stars	$23.35 -3.6%	$28.20 +20.8%	+71.6%	$12.10B	$4.72B	N/A	9,400	Positive News
RDY Dr. Reddy's Laboratories	1.4528 of 5 stars	$13.15 -1.2%	N/A	+2.2%	$11.10B	$335.93B	22.66	27,527
ARWR Arrowhead Pharmaceuticals	2.0119 of 5 stars	$81.04 +5.9%	$86.36 +6.6%	+390.6%	$10.78B	$829.45M	N/A	400	Analyst Upgrade High Trading Volume
SMMT Summit Therapeutics	3.731 of 5 stars	$14.07 +1.4%	$27.23 +93.5%	-32.0%	$10.77B	N/A	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARQT) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcutis Biotherapeutics (ARQT) Competitors

ARQT vs. ELAN, RDY, ARWR, SMMT, and NUVL

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Summary

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Arcutis Biotherapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Arcutis Biotherapeutics compare to Summit Therapeutics?

Summary

How does Arcutis Biotherapeutics compare to Nuvalent?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT vs. The Competition

Arcutis Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcutis Biotherapeutics (ARQT) Competitors

ARQT vs. ELAN, RDY, ARWR, SMMT, and NUVL

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Which has more risk and volatility, ELAN or ARQT?

Is ELAN or ARQT more profitable?

Which has preferable valuation and earnings, ELAN or ARQT?

Do analysts rate ELAN or ARQT?

Do institutionals and insiders believe in ELAN or ARQT?

Does the media refer more to ELAN or ARQT?

Summary

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Which has higher valuation & earnings, RDY or ARQT?

Does the media prefer RDY or ARQT?

Is RDY or ARQT more profitable?

Which has more risk and volatility, RDY or ARQT?

Do analysts prefer RDY or ARQT?

Do institutionals & insiders hold more shares of RDY or ARQT?

Summary

How does Arcutis Biotherapeutics compare to Arrowhead Pharmaceuticals?

Is ARQT or ARWR more profitable?

Do analysts recommend ARQT or ARWR?

Which has stronger valuation and earnings, ARQT or ARWR?

Does the media favor ARQT or ARWR?

Which has more volatility & risk, ARQT or ARWR?

Do institutionals and insiders have more ownership in ARQT or ARWR?

Summary

How does Arcutis Biotherapeutics compare to Summit Therapeutics?

Is ARQT or SMMT more profitable?

Which has more risk & volatility, ARQT or SMMT?

Does the media favor ARQT or SMMT?

Which has preferable valuation & earnings, ARQT or SMMT?

Do insiders and institutionals have more ownership in ARQT or SMMT?

Do analysts rate ARQT or SMMT?

Summary

How does Arcutis Biotherapeutics compare to Nuvalent?

Is NUVL or ARQT more profitable?

Which has higher valuation & earnings, NUVL or ARQT?

Do institutionals and insiders have more ownership in NUVL or ARQT?

Does the media refer more to NUVL or ARQT?

Do analysts prefer NUVL or ARQT?

Which has more risk & volatility, NUVL or ARQT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT vs. The Competition

Arcutis Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools